MedTrace Logo

Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma

NCT05105815 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2021-11-03

No results posted yet for this study

Summary

In this study, safety and effects of IPM001 vaccine on human hepatocellular carcinoma are going to be investigated, IPM001 is a neoantigen/tumor-specific antigen sensitized autoimmune cell injection

Conditions

Interventions

BIOLOGICAL

IPM001

IPM001 will be used against tumor cells

Sponsors & Collaborators

  • Beijing Immupeutics Medicine Technology Limited

    collaborator INDUSTRY

  • Peking University People's Hospital

    collaborator OTHER

  • Huashan Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-31
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05105815 on ClinicalTrials.gov